Lobo EV Technologies Schedules Annual Meeting After Correcting Filing Error
Lobo EV Technologies schedules its annual meeting following correction of a prior SEC filing error, reinforcing governance transparency. #LoboEV #CorporateGovernance
Topic
Finance
Finance news
Plumas Bancorp Announces Quarterly Dividend of $0.30 Per Share
Plumas Bancorp declares a $0.30 quarterly dividend per share, reflecting strong financial health and commitment to shareholder returns. #PlumasBancorp #DividendAnnouncement
Connect Biopharma Regains Nasdaq Compliance with Minimum Bid Price Rule
Connect Biopharma restores Nasdaq compliance by meeting minimum bid price requirements, stabilizing its market position. #ConnectBiopharma #NasdaqCompliance
OKYO Pharma Receives $1.9 Million Non-Dilutive Funding for Lead Drug Development
OKYO Pharma secures $1.9M non-dilutive funding to advance its lead drug candidate, accelerating clinical development. #OKYOPharma #DrugDevelopment
Semler Scientific Updates Bitcoin Holdings and ATM Stock Sales in SEC Filing
Semler Scientific reports updated Bitcoin holdings and recent ATM stock sales, reflecting strategic asset management. #SemlerScientific #BitcoinHoldings
Stereotaxis Projects Second Quarter Revenue Growth and Stable Margins
Stereotaxis forecasts Q2 revenue growth with stable margins, driven by strong demand for robotic navigation systems. #Stereotaxis #Q22025Growth
nVent Electric Executive Vice President Jon D. Lammers to Retire in April 2026
nVent Electric announces EVP Jon D. Lammers’ retirement in April 2026, marking a leadership transition. #nVentElectric #LeadershipChange
FDA Grants Breakthrough Therapy Designation to Praxis’ Relutrigine for Pediatric Epilepsy
FDA awards breakthrough therapy status to Praxis’ relutrigine, advancing treatment options for pediatric epilepsy. #PraxisTherapeutics #PediatricEpilepsy
General Electric Releases Second-Quarter 2025 Results on Company Website
General Electric reports strong Q2 2025 results with revenue growth and improved margins, highlighting operational resilience. #GeneralElectric #Q22025Results
Vigil Neuroscience Merger with Sanofi Clears U.S. Antitrust Waiting Period
Vigil Neuroscience’s merger with Sanofi clears U.S. antitrust review, advancing strategic collaboration in neuroscience therapies. #VigilNeuroscience #SanofiMerger